Shanghai Fudan Forward S&T Past Earnings Performance
Past criteria checks 0/6
Shanghai Fudan Forward S&T's earnings have been declining at an average annual rate of -35.2%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 13.9% per year.
Key information
-35.2%
Earnings growth rate
-35.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -13.9% |
| Return on equity | -0.6% |
| Net Margin | -0.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shanghai Fudan Forward S&T makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 665 | -5 | 264 | 34 |
| 31 Dec 23 | 680 | 6 | 263 | 35 |
| 30 Sep 23 | 731 | -19 | 262 | 37 |
| 30 Jun 23 | 765 | -25 | 266 | 39 |
| 31 Mar 23 | 741 | -8 | 253 | 39 |
| 31 Dec 22 | 789 | -4 | 269 | 40 |
| 30 Sep 22 | 837 | -118 | 282 | 41 |
| 30 Jun 22 | 919 | -110 | 290 | 42 |
| 31 Mar 22 | 1,011 | -104 | 316 | 49 |
| 31 Dec 21 | 1,041 | -105 | 331 | 49 |
| 30 Sep 21 | 1,005 | -68 | 322 | 50 |
| 30 Jun 21 | 994 | -62 | 333 | 54 |
| 31 Mar 21 | 979 | -68 | 329 | 48 |
| 31 Dec 20 | 940 | -60 | 314 | 51 |
| 30 Sep 20 | 975 | 38 | 331 | 60 |
| 30 Jun 20 | 986 | 37 | 358 | 58 |
| 31 Mar 20 | 1,100 | 54 | 398 | 57 |
| 31 Dec 19 | 1,400 | 56 | 437 | 53 |
| 30 Sep 19 | 1,412 | 52 | 458 | 46 |
| 30 Jun 19 | 1,406 | 52 | 476 | 42 |
| 31 Mar 19 | 1,287 | 48 | 467 | 44 |
| 31 Dec 18 | 1,008 | 43 | 450 | 41 |
| 30 Sep 18 | 931 | 48 | 427 | 34 |
| 30 Jun 18 | 854 | 44 | 338 | 52 |
| 31 Mar 18 | 798 | 43 | 279 | 40 |
| 31 Dec 17 | 736 | 42 | 228 | 33 |
| 30 Sep 17 | 710 | 28 | 193 | 26 |
| 30 Jun 17 | 701 | 33 | 187 | 0 |
| 31 Mar 17 | 687 | 40 | 180 | 0 |
| 31 Dec 16 | 671 | 38 | 177 | 0 |
| 30 Sep 16 | 691 | 60 | 169 | 0 |
| 30 Jun 16 | 676 | 57 | 170 | 0 |
| 31 Mar 16 | 676 | 53 | 162 | 0 |
| 31 Dec 15 | 718 | 52 | 156 | 0 |
| 30 Sep 15 | 809 | 44 | 155 | 0 |
| 30 Jun 15 | 891 | 42 | 150 | 0 |
| 31 Mar 15 | 975 | 41 | 159 | 0 |
| 31 Dec 14 | 1,008 | 41 | 154 | 0 |
| 30 Sep 14 | 985 | 36 | 146 | 0 |
| 30 Jun 14 | 987 | 35 | 132 | 0 |
| 31 Mar 14 | 957 | 34 | 116 | 0 |
| 31 Dec 13 | 952 | 34 | 112 | 0 |
| 30 Sep 13 | 943 | 32 | 145 | 0 |
| 30 Jun 13 | 905 | 30 | 160 | 0 |
Quality Earnings: 600624 is currently unprofitable.
Growing Profit Margin: 600624 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600624 is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.
Accelerating Growth: Unable to compare 600624's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 600624 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.1%).
Return on Equity
High ROE: 600624 has a negative Return on Equity (-0.56%), as it is currently unprofitable.